EIM
ATNM icon

Essex Investment Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Essex Investment Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-36,703
Closed -$816K – 481
2018
Q3 		$816K Buy
+36,703
New +$747K 0.1% 259

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Essex Investment Management's ATNM Position: Q4 2018 in Review

Essex Investment Management sold out of Actinium Pharmaceuticals (ATNM) in Q4 2018, closing a stake of 36,703 shares — an estimated $816K sold.

Essex Investment Management first reported a position in ATNM in Q3 2018 and held it in 1 quarter. The position peaked at $816K in Q3 2018. 43 funds tracked by Wall St. Rank hold ATNM as of Q4 2018.

  • Essex Investment Management reported no remaining Actinium Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 36,703 Actinium Pharmaceuticals shares in Q4 2018, an estimated $816K.
  • Essex Investment Management first reported a position in Actinium Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • Essex Investment Management's Actinium Pharmaceuticals position peaked at $816K in Q3 2018.
  • 43 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.